Glaukos Tech in Numerous Presentations at 2019 American Glaucoma Society

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that its products will be featured in various presentations at the American Glaucoma Society (AGS) Annual Meeting on March 14-17, 2019 at the Marriott Marquis Hotel in San Francisco.

Glaukos is sponsoring an educational symposium for surgeons during AGS entitled “The New Dawn of MIGS: Devices, Data and Techniques” on March 15, 2019 at 1:15 to 2:15 PDT in the Soma Room of the Marriott Marquis Hotel. The faculty includes Ike Ahmed, MD (Moderator); Mark Gallardo, MD; Davinder Grover, MD; and Nate Radcliffe, MD. Go here to register.

Glaukos will also be exhibiting on the showroom floor throughout AGS at booth #B6.

In addition, key surgeon poster presentations available for viewing on March 14, 2019 include:

• One-Year Outcomes of Combined Phaco and Collector Channel Targeting with Two Second-Generation Trabecular Bypass Stents (iStent inject^®) (PO001)
  Author: Paul Harasymowycz, MD
• Trabecular Micro-Bypass Stent Implantation with Cataract Extraction in Pseudoexfoliative Glaucoma: Long-Term Results (PO004)
  Authors: Tanner J. Ferguson, MD; Vance Thomson, MD; John Berdahl, MD
• Five-Year Outcomes of a Study Evaluating One, Two or Three Trabecular Micro-Bypass Stents for Open-Angle Glaucoma (OAG) (PO017)
  Author: Oluwatosin U. Smith, MD
• Three-Year Outcomes of Phacoemulsification with Implantation of Two First-Generation Trabecular Micro-Bypass Stents in Patients with OAG (PO018)
  Authors: Lucy Ma, Won I. Kim, MD
• Investigating Pre-Operative Factors that Predict Trabecular Meshwork Bypass Procedure Outcomes (PO022)
  Authors: Jason Flamendorf, MD; Jonathan S. Myers, MD; Daniel Lee, MD
• Long-Term Performance of Second-Generation Trabecular Micro-Bypass Stents (iStent inject) Implanted in Patients with Glaucoma: Four-Year Outcomes (PO025)
  Authors: Fritz H. Hengerer, MD; Jay L. Katz, MD
• Intermediate-Term Outcomes of First-Generation Trabecular Micro-Bypass Stents and Second-Generation Stents in Combination with Phacoemulsification (PO026)
  Authors: Taylor T. Lukasik, MD; Ike K. Ahmed, MD
• Single-Surgeon Experience with iStent^® Trabecular Micro-Bypass Implanted in Conjunction with Cataract Surgery: Long-Term Outcomes (PO035)
  Authors: Richard A. Supnet, MS; Mark J. Gallardo, MD
• Medium-Term Outcomes of Multiple Trabecular Micro-Bypass Stents in Combination with Phacoemulsification (PO038)
  Authors: Nicholas H. Andrew, MBBS; Ike K. Ahmed, MD
• A Prospective, Randomized Pivotal Study of Second-Generation Trabecular Micro-Bypass Stents (iStent inject) Implanted in Conjunction with Cataract Surgery (PO042)
  Author: Inder P. Singh, MD
• Evaluating Minimally Invasive Glaucoma Surgery with Trabecular Micro-Bypass Stents in African American Glaucoma Patients (PO044)
  Authors: Albert Bargoud, BA; Selena J. An, MSPH; Leon W. Herndon, MD; Albert S. Khouri, MD

Glaukos pioneered MIGS, which involves insertion of a micro-scale device from within the eye’s anterior chamber through a small corneal incision. Glaukos MIGS devices are designed to reduce IOP by restoring the natural outflow pathways for aqueous humor. In 2012, Glaukos received U.S. Food and Drug Administration (FDA) approval and launched its first MIGS device, the iStent Trabecular Micro-Bypass Stent.

https://www.marketscreener.com/GLAUKOS-CORP-22619559/news/Glaukos-Technologies-Featured-in-Numerous-Presentations-at-2019-American-Glaucoma-Society-Meeting-28160791/